

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.2	83.3	(30.4-181.2)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.2	nc	(nc-nc)	Female	3	0.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	9.1	131.5	(67.9-229.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.6	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	4.1	nc	(nc-nc)	Male	31	30.4	102.1	(69.3-144.9)
Female	4	2.9	nc	(nc-nc)	Female	20	22.8	87.8	(53.6-135.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	46	43.8	105.1	(76.9-140.2)	Male	32	25.3	126.4	(86.5-178.5)
Female	17	16.7	101.8	(59.3-163.0)	Female	27	20.3	133.0	(87.6-193.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.3	82.5	(30.1-179.6)	Male	9	6.7	134.3	(61.3-255.0)
Female	7	6.4	109.5	(43.9-225.6)	Female	6	5.3	113.1	(41.3-246.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.4	nc	(nc-nc)	Male	20	21.9	91.3	(55.7-141.0)
Female	155	153.3	101.1	(85.8-118.4)	Female	16	21.0	76.1	(43.5-123.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	5.8	nc	(nc-nc)	Male	13	15.6	83.5	(44.4-142.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	60.3	64.7	(46.0-88.5)	Female	14	16.1	87.0	(47.5-146.0)
Female	43	61.5	70.0	(50.6-94.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	13.1	84.2	(42.0-150.6)
Male	10	11.1	90.5	(43.3-166.4)	Female	9	14.6	61.7	(28.2-117.2)
Female	3	3.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	176	158.1	111.3	(95.5-129.1)
Male	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.1	nc	(nc-nc)	Male	3	10.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	7	6.8	103.5	(41.5-213.2)
Male	16	19.6	81.8	(46.7-132.8)	<u>Testis</u>				
Female	6	12.7	47.4	(17.3-103.2)	Male	3	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	6.8	nc	(nc-nc)	Male	9	5.8	155.2	(70.8-294.7)
Female	0	1.9	nc	(nc-nc)	Female	29	17.9	162.0	(108.4-232.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	13.6	117.9	(67.4-191.5)	Female	23	34.1	67.5	(42.7-101.2)
Female	12	11.2	106.8	(55.1-186.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	498	558.3	89.2	(81.5-97.4)
Male	6	9.6	62.3	(22.8-135.7)	Female	494	545.5	90.6	(82.7-98.9)
Female	1	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	45	80.0	56.2	(41.0-75.3)					
Female	55	78.6	70.0	(52.7-91.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	3	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.3	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	11.2	97.9	(48.8-175.1)
Male	0	0.2	nc	(nc-nc)	Female	9	9.0	100.1	(45.7-190.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	0	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.9	nc	(nc-nc)	Male	5	5.0	99.7	(32.1-232.7)
Female	0	2.5	nc	(nc-nc)	Female	5	4.0	125.3	(40.4-292.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	35	27.9	125.6	(87.5-174.7)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	5	3.1	160.9	(51.8-375.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.2	98.4	(49.1-176.1)	Female	0	2.8	nc	(nc-nc)
Female	12	9.1	132.1	(68.2-230.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	28	30.0	93.2	(61.9-134.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.8	nc	(nc-nc)	Female	4	6.2	nc	(nc-nc)
Female	6	2.2	274.7	(100.3-597.8)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.3	nc	(nc-nc)	Male	92	106.5	86.4	(69.6-105.9)
Female	0	0.3	nc	(nc-nc)	Female	91	93.8	97.1	(78.1-119.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
Female	2	1.9	nc	(nc-nc)	Male	92	106.5	86.4	(69.6-105.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.9	nc	(nc-nc)	Female	91	93.8	97.1	(78.1-119.2)
Female	0	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	6	14.8	40.6	(14.8-88.3)	Male	92	106.5	86.4	(69.6-105.9)
Female	12	12.7	94.1	(48.6-164.4)	Female	91	93.8	97.1	(78.1-119.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	8.8	90.8	(39.1-178.9)	Male	6	5.7	104.5	(38.2-227.5)
Female	4	3.2	nc	(nc-nc)	Female	7	4.7	150.2	(60.2-309.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.9	143.4	(57.5-295.6)
Female	37	33.0	112.3	(79.0-154.8)	Female	6	4.2	143.1	(52.2-311.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	12.6	111.0	(60.7-186.3)	Female	4	3.4	nc	(nc-nc)
Female	11	11.6	95.2	(47.4-170.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	38	33.8	112.5	(79.6-154.5)
Male	2	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.3	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.6	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.0	nc	(nc-nc)	Female	6	7.3	82.4	(30.1-179.3)
Female	5	2.3	214.1	(69.0-499.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	116	119.8	96.8	(80.0-116.1)
Male	0	2.1	nc	(nc-nc)	Female	112	112.7	99.4	(81.8-119.6)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	16.4	60.9	(29.1-112.0)					
Female	11	15.2	72.2	(36.0-129.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	21.9	91.2	(55.7-140.8)	Male	19	12.8	148.3	(89.2-231.5)
Female	6	8.2	72.9	(26.6-158.6)	Female	14	10.2	137.4	(75.0-230.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.7	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	13	11.1	117.5	(62.5-200.9)
Female	80	76.2	105.0	(83.2-130.7)	Female	8	10.5	76.4	(32.9-150.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.9	nc	(nc-nc)	Male	1	8.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	30.4	88.8	(58.5-129.1)	Female	6	8.0	74.6	(27.2-162.3)
Female	22	30.8	71.5	(44.8-108.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	6.6	nc	(nc-nc)
Male	6	5.6	107.4	(39.2-233.9)	Female	5	7.2	69.1	(22.3-161.4)
Female	1	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	88	80.3	109.6	(87.9-135.0)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	5.0	99.2	(32.0-231.6)
<u>Kidney & Renal Pelvis</u>					Female	0	3.4	nc	(nc-nc)
Male	10	9.8	101.6	(48.7-186.9)	<u>Testis</u>				
Female	6	6.3	96.0	(35.1-209.0)	Male	5	1.9	268.0	(86.4-625.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	10	9.0	111.0	(53.1-204.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.9	116.5	(50.2-229.6)	Female	16	17.0	94.0	(53.7-152.6)
Female	3	5.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	261	281.8	92.6	(81.7-104.6)
Male	5	4.9	101.8	(32.8-237.5)	Female	224	271.2	82.6	(72.1-94.1)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	39.8	57.8	(36.6-86.7)					
Female	22	38.3	57.4	(36.0-86.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	92	82.9	110.9	(89.4-136.0)	Male	21	56.2	37.4	(23.1-57.1)
Female	29	34.7	83.6	(56.0-120.1)	Female	22	50.7	43.4	(27.2-65.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	18.6	75.4	(41.2-126.5)	Male	10	13.3	75.3	(36.1-138.6)
Female	15	16.3	92.1	(51.5-151.9)	Female	14	11.0	127.8	(69.8-214.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	6	2.7	224.5	(82.0-488.6)	Male	48	48.0	100.1	(73.8-132.7)
Female	264	336.3	78.5	(69.3-88.6)	Female	45	45.8	98.3	(71.7-131.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	24	15.9	151.1	(96.8-224.8)	Male	62	33.8	183.5	(140.7-235.3)
Female					Female	22	17.0	129.5	(81.2-196.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	143	118.7	120.4	(101.5-141.9)	Female	39	35.5	109.7	(78.0-150.0)
Female	131	126.2	103.8	(86.8-123.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	25.3	90.8	(57.6-136.3)
Male	25	22.1	113.1	(73.2-166.9)	Female	29	29.9	97.1	(65.0-139.4)
Female	9	6.7	134.0	(61.1-254.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	234	317.1	73.8	(64.6-83.9)
Male	10	9.8	102.4	(49.0-188.3)	<u>Stomach</u>				
Female	6	7.9	76.3	(27.8-166.0)	Male	19	19.3	98.2	(59.1-153.4)
<u>Kidney & Renal Pelvis</u>					Female	12	13.9	86.3	(44.5-150.7)
Male	44	41.4	106.2	(77.2-142.6)	<u>Testis</u>				
Female	36	27.6	130.3	(91.3-180.4)	Male	12	18.0	66.8	(34.5-116.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	20	13.8	145.4	(88.8-224.5)	Male	12	15.9	75.4	(38.9-131.7)
Female	5	4.0	124.3	(40.1-290.1)	Female	54	51.1	105.7	(79.4-137.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	37	30.4	121.7	(85.7-167.7)	Female	68	73.8	92.1	(71.5-116.8)
Female	26	26.0	99.8	(65.2-146.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1155	1149.3	100.5	(94.8-106.5)
Male	35	20.1	173.9	(121.1-241.8)	Female	1163	1199.6	97.0	(91.5-102.7)
Female	10	7.5	132.9	(63.6-244.4)					
<u>Lung and Bronchus</u>									
Male	197	155.1	127.0	(109.9-146.0)					
Female	198	165.9	119.4	(103.3-137.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	25.2	59.6	(33.3-98.3)	Male	8	16.0	50.1	(21.6-98.7)
Female	4	9.3	nc	(nc-nc)	Female	5	12.2	41.0	(13.2-95.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	5	3.8	132.0	(42.5-308.1)	Female	4	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	6	13.6	44.1	(16.1-96.0)
Female	80	88.0	90.9	(72.1-113.2)	Female	14	11.9	117.2	(64.0-196.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.7	nc	(nc-nc)	Male	5	9.8	50.8	(16.4-118.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	32	35.5	90.2	(61.7-127.3)	Female	7	9.2	76.1	(30.5-156.8)
Female	31	33.2	93.4	(63.4-132.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	7.7	104.4	(45.0-205.8)
Male	0	6.6	nc	(nc-nc)	Female	8	8.0	100.3	(43.2-197.7)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	96.5	102.6	(83.4-124.9)
Male	5	2.3	219.3	(70.7-511.7)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	7	5.8	120.7	(48.4-248.7)
<u>Kidney & Renal Pelvis</u>					Female	2	3.6	nc	(nc-nc)
Male	16	12.1	132.4	(75.6-215.0)	<u>Testis</u>				
Female	5	7.3	68.1	(21.9-158.9)	Male	4	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.1	145.3	(53.1-316.4)	Male	6	4.2	143.6	(52.4-312.6)
Female	0	1.1	nc	(nc-nc)	Female	9	11.5	78.3	(35.7-148.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	8.3	132.7	(66.1-237.4)	Female	15	19.8	75.8	(42.4-125.1)
Female	2	6.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	311	339.3	91.7	(81.8-102.4)
Male	6	5.9	101.4	(37.0-220.7)	Female	237	311.4	76.1	(66.7-86.4)
Female	1	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	47.1	112.5	(84.2-147.1)					
Female	24	45.4	52.9	(33.9-78.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	10.5	132.9	(72.6-223.0)	Male	7	6.9	100.8	(40.4-207.7)
Female	4	3.5	nc	(nc-nc)	Female	3	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	4	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.9	nc	(nc-nc)
Female	37	38.8	95.5	(67.2-131.6)	Female	6	4.7	127.8	(46.7-278.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	9	15.3	59.0	(26.9-112.0)	Female	3	3.9	nc	(nc-nc)
Female	9	12.5	71.8	(32.8-136.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.3	nc	(nc-nc)
Male	5	2.9	173.1	(55.8-404.0)	Female	6	3.0	201.6	(73.6-438.8)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	48	41.6	115.4	(85.1-153.1)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	5	5.3	94.0	(30.3-219.3)	<u>Testis</u>				
Female	1	3.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	1.8	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	5.6	89.1	(28.7-208.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	3.5	197.4	(79.1-406.7)	Female	9	8.6	104.1	(47.5-197.6)
Female	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	147	145.5	101.0	(85.3-118.7)
Male	3	2.7	nc	(nc-nc)	Female	125	128.6	97.2	(80.9-115.8)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	19.9	125.8	(81.4-185.8)					
Female	16	17.3	92.3	(52.7-149.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	97	83.9	115.6	(93.7-141.0)	Male	42	53.6	78.4	(56.5-106.0)
Female	41	32.7	125.4	(90.0-170.1)	Female	31	46.5	66.6	(45.3-94.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.2	99.0	(57.6-158.5)	Male	15	13.2	114.0	(63.8-188.0)
Female	21	15.0	140.4	(86.9-214.7)	Female	10	10.4	96.6	(46.2-177.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.7	188.0	(60.6-438.6)	Male	54	46.0	117.3	(88.1-153.0)
Female	271	316.7	85.6	(75.7-96.4)	Female	55	42.8	128.4	(96.7-167.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	21	14.4	146.2	(90.4-223.5)	Male	42	32.1	130.6	(94.1-176.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	127	118.0	107.6	(89.7-128.0)	Female	33	33.4	98.9	(68.1-139.0)
Female	112	118.8	94.3	(77.6-113.4)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	34	21.7	156.5	(108.3-218.7)	Male	268	309.5	86.6	(76.5-97.6)
Female	7	6.3	110.6	(44.3-228.0)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	11	8.3	132.8	(66.2-237.7)	Male	9	14.5	62.1	(28.4-118.0)
Female	8	6.8	118.0	(50.8-232.5)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	37	39.9	92.7	(65.3-127.8)	Female	75	70.1	107.0	(84.1-134.1)
Female	37	26.0	142.3	(100.2-196.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	13.4	119.3	(68.1-193.7)	Male	1205	1122.2	107.4	(101.4-113.6)
Female	5	3.8	131.3	(42.3-306.4)	Female	1197	1124.6	106.4	(100.5-112.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	44	29.4	149.7	(108.7-200.9)	<u>All Sites / Types</u>				
Female	33	24.1	136.8	(94.1-192.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	19.4	123.4	(79.1-183.7)	<u>All Sites / Types</u>				
Female	7	7.1	98.9	(39.6-203.9)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	195	154.7	126.1	(109.0-145.1)	<u>All Sites / Types</u>				
Female	194	156.9	123.6	(106.8-142.3)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	17.2	98.6	(57.4-157.9)	Male	15	10.0	149.7	(83.7-246.9)
Female	8	5.5	144.6	(62.3-284.9)	Female	14	7.2	194.9	(106.4-327.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	8.7	80.8	(32.4-166.5)
Female	56	54.3	103.1	(77.9-133.9)	Female	6	7.1	84.0	(30.7-182.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.1	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	23.8	92.4	(57.9-139.8)	Female	7	5.6	124.5	(49.9-256.6)
Female	17	19.8	85.8	(49.9-137.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.2	96.3	(31.0-224.8)
Male	7	4.4	157.9	(63.3-325.4)	Female	3	4.8	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	75	64.1	117.1	(92.1-146.8)
Male	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.1	nc	(nc-nc)
Male	6	7.8	77.0	(28.1-167.5)	<u>Testis</u>				
Female	2	4.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.7	nc	(nc-nc)	Male	6	2.3	259.2	(94.7-564.2)
Female	1	0.7	nc	(nc-nc)	Female	3	6.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	5.3	187.0	(89.5-343.9)	Female	11	12.4	88.8	(44.3-159.0)
Female	2	3.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	232	222.7	104.2	(91.2-118.5)
Male	1	3.8	nc	(nc-nc)	Female	188	188.1	100.0	(86.2-115.3)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	31.8	66.0	(40.8-100.8)					
Female	27	27.2	99.1	(65.3-144.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	68	57.7	117.8	(91.5-149.4)	Male	24	36.8	65.3	(41.8-97.1)
Female	28	23.0	121.7	(80.8-175.9)	Female	21	32.1	65.4	(40.5-99.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	11.2	143.2	(81.8-232.5)	Male	10	9.0	110.6	(52.9-203.4)
Female	9	9.8	91.7	(41.8-174.1)	Female	4	7.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	27	31.3	86.3	(56.9-125.6)
Female	208	218.4	95.2	(82.7-109.1)	Female	26	29.8	87.2	(56.9-127.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	9.9	121.2	(62.5-211.7)	Male	27	21.8	124.1	(81.7-180.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	111	80.9	137.2	(112.9-165.3)	Female	15	23.0	65.2	(36.5-107.6)
Female	83	83.4	99.5	(79.3-123.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	17.3	80.7	(44.1-135.4)
Male	14	14.9	94.1	(51.4-157.8)	Female	9	19.8	45.4	(20.7-86.3)
Female	6	4.5	134.4	(49.1-292.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	183	215.0	85.1	(73.2-98.4)
Male	5	5.4	92.6	(29.8-216.1)	<u>Stomach</u>				
Female	2	4.4	nc	(nc-nc)	Male	13	13.3	97.4	(51.8-166.5)
<u>Kidney & Renal Pelvis</u>					Female	11	9.2	120.0	(59.8-214.8)
Male	24	27.3	88.0	(56.4-131.0)	<u>Testis</u>				
Female	11	18.0	61.1	(30.4-109.3)	Male	5	10.1	49.4	(15.9-115.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	9.3	75.6	(30.3-155.8)	Male	10	9.7	102.9	(49.3-189.2)
Female	1	2.7	nc	(nc-nc)	Female	35	31.4	111.5	(77.6-155.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	19.3	87.9	(51.2-140.8)	Female	39	48.5	80.5	(57.2-110.0)
Female	14	16.2	86.4	(47.2-145.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	792	770.2	102.8	(95.8-110.3)
Male	27	13.2	204.3	(134.6-297.3)	Female	719	779.7	92.2	(85.6-99.2)
Female	10	4.9	202.6	(97.0-372.6)					
<u>Lung and Bronchus</u>									
Male	123	106.8	115.2	(95.8-137.5)					
Female	99	110.1	89.9	(73.1-109.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.3	123.9	(56.5-235.2)	Male	7	4.4	158.6	(63.6-326.9)
Female	2	2.6	nc	(nc-nc)	Female	7	3.4	203.8	(81.6-419.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	42	26.0	161.3	(116.2-218.0)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	6	2.9	207.9	(75.9-452.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	10.3	97.4	(46.6-179.1)	Female	3	2.7	nc	(nc-nc)
Female	8	9.3	86.1	(37.1-169.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	23	29.1	79.1	(50.2-118.8)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.0	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	3.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	2.3	264.0	(96.4-574.6)	Female	4	6.0	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	101	97.8	103.2	(84.1-125.5)
Male	4	1.7	nc	(nc-nc)	Female	93	89.1	104.4	(84.3-127.9)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	8	13.7	58.2	(25.1-114.7)					
Female	8	12.6	63.3	(27.3-124.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	13.9	100.6	(55.0-168.9)	Male	12	11.0	109.2	(56.4-190.8)
Female	13	5.0	260.1	(138.4-444.8)	Female	14	10.0	139.4	(76.1-233.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.9	nc	(nc-nc)	Male	5	2.4	210.4	(67.8-491.1)
Female	2	3.1	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	9.2	65.2	(23.8-142.0)
Female	59	63.0	93.6	(71.3-120.8)	Female	6	7.3	82.1	(30.0-178.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.7	nc	(nc-nc)	Male	9	6.8	133.0	(60.7-252.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	26	21.2	122.4	(79.9-179.4)	Female	6	6.3	95.2	(34.8-207.3)
Female	22	18.6	118.5	(74.2-179.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.4	113.3	(36.5-264.5)
Male	11	4.0	275.6	(137.4-493.2)	Female	5	4.3	116.9	(37.7-272.7)
Female	0	1.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	56	55.4	101.0	(76.3-131.2)
Male	1	2.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.0	nc	(nc-nc)
Male	9	8.0	112.4	(51.3-213.4)	<u>Testis</u>				
Female	7	4.6	152.4	(61.1-314.0)	Male	5	4.0	126.6	(40.8-295.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2.5	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	17	11.8	143.9	(83.8-230.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	5.7	105.3	(38.4-229.1)	Female	12	13.2	91.1	(47.0-159.1)
Female	6	4.4	136.0	(49.7-296.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	215	207.5	103.6	(90.2-118.4)
Male	3	3.9	nc	(nc-nc)	Female	229	205.7	111.3	(97.4-126.7)
Female	3	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	24	26.3	91.1	(58.4-135.6)					
Female	29	24.5	118.2	(79.1-169.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	26.6	108.9	(72.9-156.4)	Male	30	16.2	185.4	(125.1-264.7)
Female	11	9.4	116.7	(58.2-208.8)	Female	29	12.9	224.4	(150.3-322.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.7	105.7	(34.1-246.7)	Male	4	4.2	nc	(nc-nc)
Female	7	4.0	176.5	(70.7-363.6)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	13.8	101.1	(55.2-169.6)
Female	98	95.4	102.8	(83.4-125.2)	Female	14	12.3	113.9	(62.2-191.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.0	201.7	(86.9-397.5)	Male	6	10.3	58.3	(21.3-126.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	37.5	120.1	(87.6-160.7)	Female	6	9.8	61.0	(22.3-132.8)
Female	41	34.4	119.3	(85.6-161.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	8.1	98.5	(42.4-194.1)
Male	3	7.0	nc	(nc-nc)	Female	9	8.2	110.4	(50.4-209.6)
Female	1	1.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	120	102.2	117.4	(97.3-140.4)
Male	1	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.4	nc	(nc-nc)	Male	2	6.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	3.7	nc	(nc-nc)
Male	14	12.5	111.7	(61.0-187.4)	<u>Testis</u>				
Female	5	7.6	65.6	(21.1-153.0)	Male	3	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.4	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	3	12.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.5	118.1	(56.6-217.3)	Female	15	21.4	70.1	(39.2-115.6)
Female	6	6.5	92.5	(33.8-201.3)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	371	353.3	105.0	(94.6-116.3)
Male	5	6.3	79.8	(25.7-186.3)	Female	337	327.2	103.0	(92.3-114.6)
Female	3	2.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	31	49.6	62.5	(42.5-88.7)					
Female	41	45.8	89.6	(64.3-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.8	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	5	3.4	145.9	(47.0-340.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	24	25.7	93.3	(59.7-138.8)	Female	6	3.5	173.5	(63.4-377.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	10.8	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	10	9.8	101.5	(48.6-186.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.4	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	29.1	82.4	(52.8-122.6)
Male	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.4	nc	(nc-nc)	Female	7	5.9	118.8	(47.6-244.9)
Female	1	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	73	101.1	72.2	(56.6-90.8)
Male	1	1.7	nc	(nc-nc)	Female	86	90.5	95.0	(76.0-117.3)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	14.5	89.9	(47.8-153.7)					
Female	12	13.1	91.6	(47.3-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	35.5	87.4	(59.4-124.1)	Male	15	23.7	63.3	(35.4-104.4)
Female	12	13.7	87.8	(45.3-153.4)	Female	20	20.1	99.6	(60.8-153.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	7.4	122.0	(55.7-231.6)	Male	5	5.7	87.8	(28.3-204.9)
Female	9	6.2	145.7	(66.5-276.5)	Female	3	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	15	20.1	74.7	(41.8-123.2)
Female	137	137.3	99.8	(83.8-118.0)	Female	16	18.0	88.9	(50.8-144.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.4	140.1	(63.9-266.0)	Male	18	14.5	124.3	(73.6-196.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	50.9	72.6	(51.1-100.1)	Female	17	14.3	119.0	(69.3-190.6)
Female	38	49.9	76.1	(53.8-104.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	10.9	55.2	(20.2-120.2)
Male	8	9.5	84.4	(36.3-166.3)	Female	16	11.8	135.9	(77.6-220.7)
Female	3	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	121	135.7	89.1	(74.0-106.5)
Male	7	3.5	200.5	(80.3-413.2)	<u>Stomach</u>				
Female	5	2.7	184.9	(59.6-431.5)	Male	5	8.3	60.3	(19.4-140.7)
<u>Kidney & Renal Pelvis</u>					Female	6	5.5	109.4	(40.0-238.2)
Male	17	17.7	96.2	(56.0-154.1)	<u>Testis</u>				
Female	12	11.0	109.5	(56.5-191.2)	Male	5	6.6	76.0	(24.5-177.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.9	nc	(nc-nc)	Male	11	6.5	169.0	(84.3-302.5)
Female	1	1.6	nc	(nc-nc)	Female	23	20.3	113.5	(71.9-170.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	12.3	97.6	(50.4-170.5)	Female	26	30.4	85.6	(55.9-125.5)
Female	7	9.9	70.4	(28.2-145.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	426	486.8	87.5	(79.4-96.2)
Male	12	8.6	139.4	(71.9-243.5)	Female	468	478.8	97.8	(89.1-107.0)
Female	2	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	70	66.0	106.0	(82.6-133.9)					
Female	59	65.3	90.3	(68.7-116.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	22.6	110.8	(71.7-163.5)	Male	26	15.7	165.9	(108.4-243.1)
Female	11	8.0	137.3	(68.4-245.6)	Female	13	13.1	99.1	(52.7-169.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.9	nc	(nc-nc)	Male	5	3.7	133.3	(43.0-311.2)
Female	4	4.0	nc	(nc-nc)	Female	5	2.6	193.5	(62.4-451.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	19	13.2	144.4	(86.9-225.6)
Female	106	93.3	113.6	(93.0-137.4)	Female	15	11.0	136.5	(76.3-225.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	13	10.3	126.7	(67.4-216.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	33.3	120.1	(85.8-163.6)	Female	10	9.4	106.4	(50.9-195.6)
Female	34	28.6	119.1	(82.4-166.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	7.1	83.9	(30.7-182.7)
Male	11	6.4	170.9	(85.2-305.7)	Female	7	6.8	103.1	(41.3-212.5)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	145	94.8	153.0	(129.1-180.0)
Male	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.7	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	4	3.0	nc	(nc-nc)
Male	9	12.0	74.9	(34.2-142.3)	<u>Testis</u>				
Female	1	7.1	nc	(nc-nc)	Male	7	3.8	185.8	(74.4-382.8)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	4.1	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	12	14.0	85.7	(44.2-149.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	8.0	100.4	(43.2-197.8)	Female	22	21.1	104.3	(65.4-158.0)
Female	5	5.9	84.3	(27.2-196.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	419	324.9	129.0	(116.9-141.9)
Male	4	6.0	nc	(nc-nc)	Female	326	305.4	106.7	(95.5-119.0)
Female	0	1.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	43.4	131.4	(99.5-170.3)					
Female	40	40.6	98.5	(70.4-134.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	20.4	171.8	(119.7-239.0)	Male	15	11.5	130.5	(73.0-215.3)
Female	6	6.9	87.4	(31.9-190.2)	Female	12	8.8	137.0	(70.7-239.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.3	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.0	120.5	(62.2-210.5)
Female	90	63.7	141.2	(113.6-173.6)	Female	5	8.6	58.0	(18.7-135.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.6	nc	(nc-nc)	Male	7	6.8	102.3	(41.0-210.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	27.5	134.5	(94.7-185.3)	Female	7	6.7	104.8	(42.0-216.0)
Female	13	24.0	54.2	(28.8-92.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.0	99.7	(36.4-217.0)
Male	10	5.1	197.3	(94.4-362.8)	Female	9	5.8	154.6	(70.6-293.5)
Female	3	1.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	98	74.1	132.2	(107.3-161.1)
Male	3	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	5	4.6	109.4	(35.3-255.4)
<u>Kidney & Renal Pelvis</u>					Female	3	2.6	nc	(nc-nc)
Male	13	8.8	146.9	(78.1-251.2)	<u>Testis</u>				
Female	6	5.4	112.0	(40.9-243.7)	Male	2	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	3.1	191.2	(69.8-416.1)	Male	2	2.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	8.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.2	96.7	(35.3-210.5)	Female	16	14.5	110.1	(62.9-178.8)
Female	9	4.6	197.8	(90.3-375.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	337	258.2	130.5	(116.9-145.2)
Male	4	4.3	nc	(nc-nc)	Female	240	226.6	105.9	(92.9-120.2)
Female	0	1.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	37.6	124.9	(91.7-166.1)					
Female	38	33.7	112.6	(79.7-154.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	9.0	77.9	(31.2-160.5)	Male	8	5.4	148.9	(64.1-293.3)
Female	1	3.2	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.5	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
Female	31	31.1	99.6	(67.7-141.4)	Female	4	4.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	12.5	151.9	(91.4-237.2)	Female	3	3.2	nc	(nc-nc)
Female	11	11.4	96.5	(48.1-172.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	35.1	88.4	(60.0-125.4)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	5	4.2	119.9	(38.6-279.8)	<u>Testis</u>				
Female	3	2.5	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	6	3.8	155.9	(56.9-339.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.8	nc	(nc-nc)	Female	7	7.1	98.3	(39.4-202.5)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	115	119.0	96.6	(79.8-116.0)
Male	2	2.1	nc	(nc-nc)	Female	97	107.9	89.9	(72.9-109.7)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.8	77.3	(41.1-132.1)					
Female	12	15.5	77.3	(39.9-135.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.3	77.4	(33.3-152.6)	Male	5	6.8	73.8	(23.8-172.2)
Female	5	4.1	122.1	(39.4-285.0)	Female	8	5.9	134.6	(57.9-265.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	3	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	6	5.7	104.4	(38.1-227.2)
Female	40	41.5	96.4	(68.9-131.3)	Female	8	5.4	148.4	(63.9-292.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	1.9	262.5	(84.6-612.6)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	14.8	54.1	(23.3-106.6)	Female	8	4.3	186.4	(80.3-367.4)
Female	9	14.9	60.4	(27.6-114.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.2	nc	(nc-nc)
Male	3	2.8	nc	(nc-nc)	Female	6	3.5	170.2	(62.2-370.5)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	28	39.3	71.3	(47.4-103.0)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	3	5.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	3.3	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	5	6.0	83.8	(27.0-195.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.5	nc	(nc-nc)	Female	12	9.2	130.4	(67.3-227.9)
Female	5	2.9	170.7	(55.0-398.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	118	140.4	84.1	(69.6-100.7)
Male	2	2.5	nc	(nc-nc)	Female	155	143.6	107.9	(91.6-126.3)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	19.1	104.5	(63.8-161.3)					
Female	17	19.8	85.9	(50.0-137.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.5	104.6	(52.2-187.3)	Male	11	7.5	147.5	(73.5-264.0)
Female	5	3.7	134.8	(43.4-314.5)	Female	8	6.1	131.4	(56.6-258.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	6.3	111.4	(44.6-229.5)
Female	55	43.9	125.3	(94.4-163.2)	Female	2	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	8	4.9	162.5	(70.0-320.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	15.7	114.9	(68.1-181.6)	Female	4	4.4	nc	(nc-nc)
Female	17	13.5	125.7	(73.2-201.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3.3	179.8	(65.6-391.3)
Male	3	3.0	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	43.8	134.7	(102.5-173.7)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.4	nc	(nc-nc)
Male	5	5.7	87.3	(28.1-203.7)	<u>Testis</u>				
Female	2	3.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.9	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	7	6.5	106.9	(42.8-220.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.8	131.0	(42.2-305.7)	Female	11	9.6	114.9	(57.3-205.7)
Female	3	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	184	152.4	120.7	(103.9-139.5)
Male	3	2.9	nc	(nc-nc)	Female	150	142.6	105.2	(89.0-123.4)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	20.3	113.4	(71.8-170.1)					
Female	17	18.5	92.0	(53.6-147.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	75	68.1	110.2	(86.7-138.1)	Male	43	39.6	108.6	(78.6-146.2)
Female	46	27.6	166.7	(122.1-222.4)	Female	34	34.4	98.9	(68.5-138.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	11.5	60.9	(24.4-125.4)	Male	7	10.3	68.0	(27.3-140.2)
Female	14	10.6	131.7	(71.9-220.9)	Female	11	8.7	126.2	(62.9-225.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	33	34.3	96.3	(66.3-135.2)
Female	295	242.7	121.5	(108.1-136.2)	Female	35	34.8	100.5	(70.0-139.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	10.0	80.4	(34.6-158.4)	Male	21	23.1	90.9	(56.2-138.9)
					Female	11	12.6	87.2	(43.5-156.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	107	92.5	115.6	(94.7-139.7)	Female	21	25.9	81.0	(50.1-123.8)
Female	92	100.5	91.5	(73.8-112.2)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	20	16.8	119.2	(72.8-184.1)	Male	23	20.0	114.8	(72.7-172.2)
Female	7	5.4	130.1	(52.1-268.1)	Female	18	23.9	75.2	(44.5-118.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	5.2	134.2	(53.8-276.6)	Male	198	239.9	82.5	(71.4-94.9)
Female	5	4.4	112.5	(36.3-262.6)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	26	29.8	87.3	(57.0-127.9)	Male	14	15.5	90.1	(49.2-151.3)
Female	17	20.7	82.1	(47.8-131.5)	Female	14	11.1	125.8	(68.7-211.2)
<u>Larynx</u>					<u>Testis</u>				
Male	13	10.3	126.3	(67.2-216.0)	Male	7	8.8	79.9	(32.0-164.6)
Female	3	3.0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	21	21.4	98.1	(60.7-149.9)	Male	12	9.5	126.7	(65.4-221.4)
Female	19	18.6	102.1	(61.4-159.4)	Female	40	31.0	128.9	(92.1-175.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	14.3	111.7	(63.8-181.4)	Female	63	54.0	116.6	(89.6-149.2)
Female	11	5.8	189.1	(94.2-338.3)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	142	124.0	114.5	(96.4-134.9)	Male	871	863.3	100.9	(94.3-107.8)
Female	127	130.2	97.5	(81.3-116.0)	Female	960	889.7	107.9	(101.2-114.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.9	100.9	(48.3-185.5)	Male	5	7.1	70.5	(22.7-164.6)
Female	5	3.8	129.9	(41.9-303.2)	Female	9	6.3	143.7	(65.6-272.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	12	6.0	200.6	(103.5-350.4)
Female	40	42.9	93.1	(66.5-126.8)	Female	8	5.2	153.0	(65.9-301.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	235.3	(75.8-549.1)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	14.7	88.5	(47.1-151.3)	Female	4	4.4	nc	(nc-nc)
Female	20	14.1	141.5	(86.4-218.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	2.8	nc	(nc-nc)	Male	58	39.8	145.9	(110.8-188.6)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	93.6	(30.2-218.5)	Female	10	9.2	109.0	(52.2-200.5)
Female	0	3.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.7	nc	(nc-nc)	Male	152	142.2	106.9	(90.5-125.3)
Female	0	0.5	nc	(nc-nc)	Female	142	143.8	98.8	(83.2-116.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.7	135.9	(43.8-317.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Lung and Bronchus</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	18.8	74.3	(40.6-124.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	18.6	91.2	(53.1-146.1)	<u>Uteri Corpus and Uterus, NOS</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	32.7	85.7	(57.0-123.9)	Male	28	19.7	142.0	(94.3-205.2)
Female	14	13.3	105.1	(57.4-176.3)	Female	23	16.9	135.7	(86.0-203.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.8	nc	(nc-nc)	Male	5	5.1	98.9	(31.9-230.7)
Female	7	5.2	133.5	(53.5-275.0)	Female	3	4.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	22	16.9	129.9	(81.4-196.7)
Female	114	121.6	93.8	(77.4-112.7)	Female	15	16.9	88.7	(49.6-146.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.1	nc	(nc-nc)	Male	12	11.9	100.8	(52.0-176.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	46	45.4	101.3	(74.2-135.1)	Female	10	12.9	77.8	(37.2-143.1)
Female	50	49.1	101.9	(75.7-134.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	9.8	81.9	(35.3-161.4)
Male	5	8.3	60.4	(19.5-140.9)	Female	9	11.6	77.5	(35.4-147.2)
Female	4	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	128	118.1	108.4	(90.4-128.8)
Male	3	2.4	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	8	7.5	106.1	(45.7-209.1)
<u>Kidney & Renal Pelvis</u>					Female	4	5.4	nc	(nc-nc)
Male	23	14.9	154.7	(98.0-232.1)	<u>Testis</u>				
Female	13	10.1	128.2	(68.2-219.2)	Male	2	4.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.1	nc	(nc-nc)	Male	6	4.8	124.6	(45.5-271.2)
Female	1	1.5	nc	(nc-nc)	Female	13	15.5	83.6	(44.5-143.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	10.5	104.9	(52.3-187.8)	Female	22	26.9	81.9	(51.3-124.0)
Female	6	9.1	65.7	(24.0-143.0)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	440	422.9	104.0	(94.5-114.2)
Male	6	7.3	82.0	(29.9-178.4)	Female	426	437.4	97.4	(88.4-107.1)
Female	4	2.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	60	59.5	100.9	(77.0-129.9)					
Female	68	62.6	108.7	(84.4-137.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.6	nc	(nc-nc)	Male	5	3.4	148.1	(47.7-345.7)
Female	2	1.6	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	15	19.0	78.9	(44.1-130.1)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.0	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	6.9	72.2	(23.3-168.5)	Female	2	1.9	nc	(nc-nc)
Female	7	5.7	121.8	(48.8-251.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	21	18.9	110.9	(68.6-169.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	2.5	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.7	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.3	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	7	8.7	80.3	(32.2-165.5)	Male	59	67.1	88.0	(67.0-113.5)
Female	6	7.7	77.8	(28.4-169.4)	Female	49	61.6	79.6	(58.8-105.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.3	79.9	(25.8-186.5)	Male	5	4.1	122.1	(39.3-284.8)
Female	5	2.1	238.9	(77.0-557.5)	Female	1	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	29	23.4	123.7	(82.8-177.7)	Female	2	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	9.0	77.9	(31.2-160.5)	Female	4	2.4	nc	(nc-nc)
Female	13	7.4	174.9	(93.0-299.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	24.3	119.3	(79.9-171.4)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.1	nc	(nc-nc)	Female	7	5.2	134.8	(54.0-277.7)
Female	3	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	82	85.6	95.7	(76.1-118.8)
Male	1	1.5	nc	(nc-nc)	Female	87	77.7	111.9	(89.6-138.0)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	9	11.7	77.1	(35.2-146.4)					
Female	12	10.5	114.2	(59.0-199.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	60	49.8	120.6	(92.0-155.2)	Male	26	30.2	86.0	(56.2-126.1)
Female	20	20.1	99.6	(60.8-153.8)	Female	19	26.0	72.9	(43.9-113.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	9.2	141.9	(75.5-242.7)	Male	12	7.7	156.4	(80.7-273.2)
Female	8	8.2	97.6	(42.0-192.3)	Female	10	6.4	156.8	(75.1-288.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	23	26.1	88.1	(55.8-132.2)
Female	165	184.0	89.7	(76.5-104.5)	Female	19	25.7	73.9	(44.5-115.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	7.8	nc	(nc-nc)	Male	19	18.1	105.0	(63.2-164.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	74	69.0	107.2	(84.2-134.6)	Female	16	19.5	82.2	(47.0-133.5)
Female	77	73.6	104.6	(82.5-130.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	17	14.8	114.5	(66.7-183.4)
Male	11	12.6	87.4	(43.6-156.3)	Female	19	17.5	108.8	(65.5-169.9)
Female	7	3.9	178.5	(71.5-367.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	175	177.7	98.5	(84.4-114.2)
Male	3	4.1	nc	(nc-nc)	<u>Stomach</u>				
Female	4	3.3	nc	(nc-nc)	Male	9	11.5	78.4	(35.8-148.8)
<u>Kidney & Renal Pelvis</u>					Female	3	8.1	nc	(nc-nc)
Male	27	22.8	118.6	(78.2-172.6)	<u>Testis</u>				
Female	16	15.4	103.8	(59.3-168.6)	Male	12	6.8	176.6	(91.2-308.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	13	7.7	168.6	(89.7-288.4)	Male	9	7.5	119.5	(54.5-226.9)
Female	2	2.2	nc	(nc-nc)	Female	26	24.3	107.0	(69.8-156.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	16.4	91.7	(51.3-151.2)	Female	48	40.4	118.8	(87.6-157.5)
Female	10	14.0	71.3	(34.2-131.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	667	645.1	103.4	(95.7-111.6)
Male	13	11.1	117.5	(62.5-200.9)	Female	642	663.3	96.8	(89.4-104.6)
Female	2	4.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	80	90.9	88.0	(69.7-109.5)					
Female	91	95.0	95.8	(77.2-117.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	18.7	128.5	(82.3-191.2)	Male	20	12.7	158.0	(96.5-244.0)
Female	11	7.2	153.8	(76.7-275.2)	Female	11	10.9	101.3	(50.5-181.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.0	124.5	(40.1-290.4)	Male	2	3.0	nc	(nc-nc)
Female	5	3.4	148.8	(48.0-347.3)	Female	4	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	14	10.8	130.1	(71.1-218.3)
Female	54	74.4	72.6	(54.5-94.7)	Female	16	9.6	167.0	(95.4-271.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	3.5	nc	(nc-nc)	Male	6	8.0	75.0	(27.4-163.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	34	27.2	125.0	(86.6-174.7)	Female	10	7.7	129.7	(62.1-238.6)
Female	29	26.3	110.2	(73.8-158.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	5.8	103.5	(37.8-225.2)
Male	8	5.1	156.4	(67.3-308.1)	Female	9	6.2	145.6	(66.4-276.4)
Female	3	1.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	80	73.0	109.5	(86.8-136.3)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	4.4	114.3	(36.8-266.7)
<u>Kidney & Renal Pelvis</u>					Female	3	2.9	nc	(nc-nc)
Male	10	9.5	105.1	(50.3-193.3)	<u>Testis</u>				
Female	10	5.9	170.9	(81.8-314.3)	Male	1	3.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	16	11.1	143.7	(82.1-233.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	6.6	121.0	(52.1-238.3)	Female	15	16.3	91.7	(51.3-151.3)
Female	4	5.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	319	260.3	122.5	(109.5-136.8)
Male	3	4.7	nc	(nc-nc)	Female	266	256.1	103.9	(91.7-117.1)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	34.9	163.1	(123.5-211.3)					
Female	36	34.4	104.8	(73.4-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	1	2.4	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	6	8.3	72.1	(26.3-157.0)
Male	0	0.2	nc	(nc-nc)	Female	4	6.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.0	87.6	(35.1-180.5)	Male	4	5.8	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)	Female	6	3.9	152.0	(55.5-330.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.9	122.7	(44.8-267.1)
Female	36	28.4	126.8	(88.8-175.5)	Female	6	3.5	171.1	(62.5-372.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	11.8	68.0	(29.3-134.1)	Female	1	2.9	nc	(nc-nc)
Female	10	9.3	107.5	(51.5-197.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	31.4	105.0	(72.2-147.4)
Male	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.0	nc	(nc-nc)
Male	0	4.2	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	1.4	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	2.9	nc	(nc-nc)	Female	6	6.4	93.4	(34.1-203.3)
Female	2	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	111	114.6	96.9	(79.7-116.7)
Male	4	2.1	nc	(nc-nc)	Female	109	95.3	114.4	(93.9-138.0)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	15.0	99.7	(55.7-164.4)					
Female	21	13.2	159.6	(98.7-243.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	45	26.8	167.9	(122.5-224.7)	Male	10	17.5	57.3	(27.4-105.3)
Female	8	10.8	74.0	(31.9-145.9)	Female	14	15.3	91.6	(50.0-153.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.4	110.5	(40.4-240.6)	Male	4	4.3	nc	(nc-nc)
Female	10	4.7	211.5	(101.2-388.9)	Female	3	3.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	11	14.9	73.9	(36.8-132.2)
Female	105	105.2	99.8	(81.6-120.8)	Female	16	14.2	112.9	(64.5-183.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	7	4.8	147.2	(59.0-303.3)	Male	5	10.8	46.4	(14.9-108.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	43	38.3	112.3	(81.3-151.3)	Female	10	11.0	90.6	(43.4-166.6)
Female	37	40.1	92.2	(64.9-127.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	8.2	nc	(nc-nc)
Male	10	7.1	140.4	(67.2-258.3)	Female	6	9.4	63.8	(23.3-138.8)
Female	2	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	101.1	97.9	(79.6-119.2)
Male	0	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	4	2.0	nc	(nc-nc)	Male	10	6.3	159.9	(76.6-294.1)
<u>Kidney & Renal Pelvis</u>					Female	6	4.4	135.0	(49.3-293.9)
Male	15	13.1	114.2	(63.9-188.3)	<u>Testis</u>				
Female	9	8.5	105.8	(48.3-200.9)	Male	3	4.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.4	nc	(nc-nc)	Male	5	4.7	107.2	(34.5-250.2)
Female	2	1.2	nc	(nc-nc)	Female	15	15.0	100.3	(56.1-165.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	9.2	108.7	(52.1-200.0)	Female	18	23.1	77.8	(46.1-123.0)
Female	8	7.8	102.1	(44.0-201.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	362	363.4	99.6	(89.6-110.4)
Male	7	6.5	108.1	(43.3-222.7)	Female	366	371.7	98.5	(88.6-109.1)
Female	2	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	52	49.8	104.5	(78.0-137.0)					
Female	49	50.9	96.3	(71.2-127.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.6	102.5	(58.6-166.5)	Male	9	9.6	93.7	(42.7-177.8)
Female	5	6.3	79.6	(25.6-185.7)	Female	3	8.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	2.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.2	97.1	(41.8-191.3)
Female	64	57.8	110.7	(85.2-141.3)	Female	6	8.0	75.2	(27.4-163.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.4	nc	(nc-nc)	Male	9	5.9	152.4	(69.6-289.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	20	21.9	91.5	(55.8-141.3)	Female	5	6.1	81.7	(26.3-190.7)
Female	21	23.0	91.2	(56.5-139.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	4.1	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	4	5.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	57	58.3	97.8	(74.1-126.7)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	7.3	68.8	(22.2-160.6)	Male	5	3.6	139.3	(44.9-325.2)
Female	5	4.8	104.4	(33.7-243.7)	Female	1	2.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	3	2.5	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	5.1	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	5	4.3	116.1	(37.4-270.9)	Female	3	7.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.6	nc	(nc-nc)	Female	15	12.9	116.2	(65.0-191.7)
Female	0	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	30	28.7	104.6	(70.5-149.3)	Male	198	205.9	96.2	(83.2-110.5)
Female	45	29.6	152.2	(111.0-203.6)	Female	208	207.5	100.2	(87.1-114.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.7	135.1	(61.6-256.5)	Male	5	4.8	104.7	(33.8-244.4)
Female	3	2.5	nc	(nc-nc)	Female	7	4.2	168.3	(67.4-346.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	32	29.1	109.8	(75.1-155.0)	Female	1	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.0	80.3	(34.6-158.2)	Female	3	2.9	nc	(nc-nc)
Female	7	8.7	80.1	(32.1-165.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	31	28.3	109.5	(74.4-155.5)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	5	3.7	136.7	(44.0-319.0)	Male	3	1.6	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	2.4	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	6	4.5	132.5	(48.4-288.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.8	nc	(nc-nc)	Female	2	6.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	15	12.9	116.0	(64.9-191.3)	Male	110	97.6	112.7	(92.6-135.9)
Female	14	12.4	112.5	(61.4-188.7)	Female	95	94.8	100.3	(81.1-122.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	1.9	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	8	8.5	94.6	(40.7-186.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	2.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	7.7	116.5	(53.1-221.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	3.6	137.1	(44.2-319.9)	Male	35	28.0	124.9	(87.0-173.7)
Female	5	3.7	135.7	(43.7-316.8)	Female	25	28.4	88.0	(56.9-129.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	30.5	75.4	(47.8-113.2)	Male	35	18.3	191.7	(133.5-266.6)
Female	14	12.3	114.3	(62.4-191.7)	Female	32	15.7	203.8	(139.3-287.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.8	(40.1-238.9)	Male	3	4.7	nc	(nc-nc)
Female	4	5.0	nc	(nc-nc)	Female	10	3.9	256.9	(123.0-472.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	22	15.8	139.2	(87.2-210.8)
Female	135	113.5	118.9	(99.7-140.8)	Female	21	15.6	134.2	(83.1-205.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.6	nc	(nc-nc)	Male	15	11.1	135.5	(75.8-223.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	51	42.3	120.5	(89.7-158.4)	Female	10	12.0	83.6	(40.0-153.7)
Female	49	45.4	107.9	(79.8-142.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	9.1	65.9	(24.1-143.5)
Male	5	7.7	65.0	(20.9-151.7)	Female	6	10.7	56.0	(20.4-121.8)
Female	3	2.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	113	108.7	103.9	(85.6-124.9)
Male	3	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.9	nc	(nc-nc)	Male	7	7.0	99.4	(39.8-204.8)
<u>Kidney & Renal Pelvis</u>					Female	5	5.0	99.5	(32.1-232.1)
Male	13	13.8	94.0	(50.0-160.8)	<u>Testis</u>				
Female	15	9.4	160.3	(89.7-264.5)	Male	5	3.5	142.0	(45.7-331.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	5	4.7	106.1	(34.2-247.7)	Male	6	4.4	135.7	(49.5-295.3)
Female	0	1.4	nc	(nc-nc)	Female	19	14.5	131.4	(79.1-205.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	9.9	60.5	(22.1-131.8)	Female	23	24.7	93.0	(58.9-139.6)
Female	10	8.5	117.0	(56.0-215.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	392	392.8	99.8	(90.2-110.2)
Male	11	6.8	161.4	(80.4-288.7)	Female	454	405.6	111.9	(101.9-122.7)
Female	2	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	55.4	54.1	(36.5-77.3)					
Female	55	57.4	95.8	(72.1-124.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	8.3	71.9	(26.2-156.4)	Male	10	5.7	175.0	(83.8-321.9)
Female	5	3.0	165.2	(53.2-385.4)	Female	6	4.6	129.2	(47.2-281.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	4.8	nc	(nc-nc)
Female	30	32.8	91.3	(61.6-130.4)	Female	8	4.1	195.7	(84.3-385.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.5	nc	(nc-nc)	Male	7	3.7	188.8	(75.6-389.0)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	12.2	106.3	(56.5-181.8)	Female	4	3.4	nc	(nc-nc)
Female	9	11.0	81.7	(37.3-155.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	6	2.6	230.5	(84.2-501.8)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	32	33.8	94.6	(64.7-133.6)
Male	3	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	4.4	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.9	nc	(nc-nc)	Female	4	7.3	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	110	118.1	93.2	(76.6-112.3)
Male	0	2.2	nc	(nc-nc)	Female	107	110.6	96.7	(79.3-116.9)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	15.9	113.2	(67.1-179.0)					
Female	10	14.9	67.1	(32.1-123.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.0	69.9	(28.0-144.1)	Male	3	6.1	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.8	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	31	36.9	84.0	(57.1-119.3)	Female	5	5.1	98.0	(31.6-228.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	14.0	78.8	(39.3-141.0)	Female	6	3.9	153.5	(56.1-334.2)
Female	13	14.5	89.7	(47.7-153.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.0	166.2	(53.6-387.9)
Male	3	2.6	nc	(nc-nc)	Female	4	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	25	36.7	68.1	(44.0-100.5)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	5	4.6	108.6	(35.0-253.4)	<u>Testis</u>				
Female	3	3.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	4.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.2	155.2	(50.0-362.1)	Female	7	8.3	84.4	(33.8-173.8)
Female	2	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	109	130.9	83.3	(68.4-100.5)
Male	0	2.3	nc	(nc-nc)	Female	114	132.4	86.1	(71.0-103.4)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.4	97.7	(57.8-154.3)					
Female	15	19.3	77.6	(43.4-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.4	nc	(nc-nc)	Male	3	0.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	8	4.4	180.6	(77.8-355.9)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.0	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.4	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	8	5.8	138.1	(59.5-272.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	5	2.7	182.7	(58.9-426.4)	Male	25	19.2	129.9	(84.0-191.8)
Female	0	2.1	nc	(nc-nc)	Female	11	14.6	75.4	(37.6-135.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	5	3.0	167.0	(53.8-389.8)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.2	nc	(nc-nc)	Male	10	12.0	83.2	(39.8-153.0)
Female	0	0.1	nc	(nc-nc)	Female	10	9.5	104.7	(50.1-192.7)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	4	1.6	nc	(nc-nc)	Male	10	12.0	83.2	(39.8-153.0)
Female	1	1.3	nc	(nc-nc)	Female	10	9.5	104.7	(50.1-192.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	1.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.1	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	2	3.4	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.9	135.1	(58.2-266.1)	Male	4	3.4	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	19	18.6	102.2	(61.5-159.5)	Female	1	2.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	2.1	291.3	(106.4-634.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	8.1	147.9	(76.3-258.3)	Female	3	1.9	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	22	20.9	105.3	(66.0-159.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.6	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.9	nc	(nc-nc)	Female	2	4.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	1.8	nc	(nc-nc)	Male	82	74.4	110.2	(87.6-136.8)
Female	2	1.3	nc	(nc-nc)	Female	64	65.7	97.5	(75.0-124.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.3	nc	(nc-nc)	Male	82	74.4	110.2	(87.6-136.8)
Female	0	0.4	nc	(nc-nc)	Female	64	65.7	97.5	(75.0-124.4)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	8	10.7	75.1	(32.3-147.9)	Male	82	74.4	110.2	(87.6-136.8)
Female	16	9.4	170.8	(97.5-277.3)	Female	64	65.7	97.5	(75.0-124.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	8.7	126.3	(63.0-226.0)	Male	14	6.2	226.8	(123.9-380.5)
Female	7	3.2	218.3	(87.5-449.8)	Female	5	5.1	98.2	(31.6-229.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	5.2	155.0	(66.7-305.4)
Female	43	33.4	128.7	(93.1-173.4)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	1.7	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	12.7	133.8	(77.9-214.2)	Female	7	3.4	203.6	(81.6-419.6)
Female	24	11.5	209.1	(133.9-311.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.7	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	64	34.3	186.6	(143.7-238.3)
Male	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	1	4.6	nc	(nc-nc)	<u>Testis</u>				
Female	2	2.6	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	5.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	5	7.3	68.9	(22.2-160.7)
Female	2	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	156	123.4	126.4	(107.3-147.9)
Male	1	2.2	nc	(nc-nc)	Female	133	115.3	115.4	(96.6-136.7)
Female	2	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	16.6	72.5	(37.4-126.6)					
Female	10	15.6	64.0	(30.6-117.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	35.6	78.7	(52.3-113.7)	Male	38	22.2	170.8	(120.9-234.5)
Female	18	14.2	126.9	(75.2-200.6)	Female	18	19.4	92.9	(55.1-146.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	6.7	178.3	(92.0-311.5)	Male	7	5.6	125.4	(50.2-258.4)
Female	8	6.0	134.1	(57.8-264.3)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	16	19.0	84.4	(48.2-137.1)
Female	136	136.8	99.4	(83.4-117.6)	Female	16	18.3	87.3	(49.9-141.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.0	83.3	(26.9-194.5)	Male	11	13.6	81.1	(40.4-145.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	49.9	104.2	(77.8-136.6)	Female	13	14.3	91.2	(48.5-156.0)
Female	56	51.5	108.7	(82.1-141.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	10.8	92.9	(44.5-170.8)
Male	9	9.3	96.9	(44.2-183.9)	Female	11	12.2	90.0	(44.8-161.0)
Female	2	2.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	136	134.5	101.1	(84.8-119.6)
Male	3	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2.4	nc	(nc-nc)	Male	4	8.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	6	5.6	106.2	(38.8-231.3)
Male	15	16.9	88.7	(49.6-146.3)	<u>Testis</u>				
Female	12	11.2	107.5	(55.5-187.8)	Male	7	5.0	139.9	(56.1-288.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	5.8	173.3	(82.9-318.7)	Male	6	5.7	105.4	(38.5-229.4)
Female	1	1.7	nc	(nc-nc)	Female	27	18.7	144.2	(95.0-209.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	11.7	85.6	(41.0-157.4)	Female	21	30.3	69.2	(42.8-105.8)
Female	13	9.9	130.7	(69.5-223.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	461	474.3	97.2	(88.5-106.5)
Male	4	8.2	nc	(nc-nc)	Female	488	481.9	101.3	(92.5-110.7)
Female	1	3.0	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	51	66.4	76.8	(57.2-101.0)					
Female	74	68.0	108.8	(85.4-136.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	37.5	90.7	(62.8-126.7)	Male	30	21.9	137.3	(92.6-196.0)
Female	11	15.2	72.2	(36.0-129.3)	Female	25	18.4	136.2	(88.1-201.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.4	156.2	(74.8-287.2)	Male	4	5.7	nc	(nc-nc)
Female	6	5.8	103.2	(37.7-224.7)	Female	6	4.8	124.5	(45.5-271.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	18	19.0	95.0	(56.2-150.1)
Female	163	134.6	121.1	(103.2-141.2)	Female	34	19.1	177.8	(123.1-248.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	5.3	nc	(nc-nc)	Male	11	13.2	83.4	(41.6-149.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	45	51.6	87.1	(63.6-116.6)	Female	12	14.3	83.7	(43.2-146.2)
Female	60	57.2	104.9	(80.1-135.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	12	11.1	107.7	(55.6-188.1)
Male	5	9.3	53.5	(17.2-124.8)	Female	17	13.4	126.8	(73.8-203.0)
Female	2	3.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	148	132.6	111.6	(94.4-131.1)
Male	5	2.5	203.6	(65.6-475.0)	<u>Stomach</u>				
Female	3	2.0	nc	(nc-nc)	Male	3	8.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	6.4	nc	(nc-nc)
Male	16	16.6	96.2	(54.9-156.2)	<u>Testis</u>				
Female	10	11.2	89.3	(42.8-164.2)	Male	4	3.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.7	nc	(nc-nc)	Male	11	5.1	216.5	(107.9-387.5)
Female	1	1.6	nc	(nc-nc)	Female	20	16.0	124.8	(76.2-192.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	11.9	134.4	(76.7-218.2)	Female	24	29.5	81.3	(52.0-120.9)
Female	9	10.5	85.7	(39.1-162.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	463	476.3	97.2	(88.6-106.5)
Male	7	8.2	85.8	(34.4-176.9)	Female	527	489.8	107.6	(98.6-117.2)
Female	2	3.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	47	67.8	69.4	(51.0-92.2)					
Female	60	69.5	86.3	(65.8-111.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.1	nc	(nc-nc)	Male	5	3.4	149.0	(48.0-347.6)
Female	0	0.0	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)					
Female	0	0.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	110	105.4	104.4	(85.8-125.8)	Male	27	62.4	43.3	(28.5-63.0)
Female	44	44.3	99.4	(72.2-133.5)	Female	26	55.5	46.9	(30.6-68.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	23	18.8	122.1	(77.4-183.3)	Male	14	16.1	87.2	(47.6-146.3)
Female	17	17.7	96.3	(56.1-154.2)	Female	15	14.0	107.3	(60.0-177.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.3	nc	(nc-nc)	Male	52	54.1	96.0	(71.7-126.0)
Female	309	387.1	79.8	(71.2-89.2)	Female	44	56.1	78.4	(57.0-105.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	22	16.1	136.8	(85.7-207.2)	Male	40	36.7	109.0	(77.9-148.5)
Female	25	20.2	123.7	(80.1-182.7)	Female	25	20.2	123.7	(80.1-182.7)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	143	144.4	99.0	(83.5-116.7)	Female	43	41.6	103.5	(74.9-139.4)
Female	171	162.2	105.4	(90.2-122.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	40	31.2	128.3	(91.7-174.7)
Male	26	26.2	99.3	(64.8-145.5)	Female	41	38.5	106.5	(76.4-144.5)
Female	5	8.6	57.9	(18.7-135.2)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	332	373.2	88.9	(79.6-99.1)
Male	8	8.7	92.2	(39.7-181.7)	<u>Stomach</u>				
Female	7	7.4	94.0	(37.7-193.7)	Male	39	24.2	161.3	(114.7-220.5)
<u>Kidney & Renal Pelvis</u>					Female	24	18.1	132.9	(85.2-197.8)
Male	43	46.8	91.9	(66.5-123.8)	<u>Testis</u>				
Female	33	33.1	99.6	(68.5-139.8)	Male	12	14.4	83.3	(43.0-145.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	19	16.1	118.2	(71.1-184.6)	Male	12	15.2	79.1	(40.8-138.2)
Female	4	4.8	nc	(nc-nc)	Female	24	50.3	47.7	(30.6-71.0)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	36	34.4	104.6	(73.3-144.8)	Female	88	85.8	102.6	(82.3-126.4)
Female	26	30.8	84.5	(55.2-123.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1331	1350.1	98.6	(93.4-104.0)
Male	37	22.6	163.8	(115.3-225.7)	Female	1283	1428.1	89.8	(85.0-94.9)
Female	10	9.4	106.4	(51.0-195.8)					
<u>Lung and Bronchus</u>									
Male	225	191.7	117.4	(102.5-133.7)					
Female	201	207.5	96.9	(83.9-111.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	5	3.4	146.4	(47.2-341.7)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	12.6	79.4	(38.0-146.0)
Male	0	0.2	nc	(nc-nc)	Female	10	11.8	84.6	(40.5-155.7)
Female	1	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	2	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	5	6.2	81.2	(26.2-189.4)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	2.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	5	2.2	232.0	(74.8-541.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	8.1	86.1	(34.5-177.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	3.9	nc	(nc-nc)	Male	19	27.8	68.4	(41.2-106.8)
Female	4	3.0	nc	(nc-nc)	Female	22	21.1	104.3	(65.3-157.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2002-2006

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	4.8	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	13	16.4	79.2	(42.1-135.5)
Male	0	0.3	nc	(nc-nc)	Female	12	12.6	95.5	(49.3-166.8)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	2.2	nc	(nc-nc)					
Female	2	1.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;